Despite treatment advancements with tyrosine kinase inhibitors (TKIs), there remains an unmet need for patients with #ChronicMyeloidLeukemia who develop resistance to or hard-to-treat mutations following these therapies. We are committed to these patients, always aiming to pursue potential new treatment options.
We’ve announced an option agreement with Ascentage Pharma that will allow us to enter into a future exclusive global license agreement for its investigational therapy currently in development for #ChronicMyeloidLeukemia (CML) and other #HematologicalCancers. If exercised, the option would allow Takeda to secure rights to develop and commercialize the therapy in all indications and territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Read more here: https://lnkd.in/emdra3rS
Head Medical Affairs Oncology | Life Sciences
2moThis is an exciting news Awny! 👏🏼👍🏼